Friday, August 1st, 2025

Singapore Airlines Faces Earnings Downdrift Amid Increased Competition

Date: October 22, 2024
Broker: CGS International Securities


Overview of Singapore Airlines (SIA)

Singapore Airlines (SIA) is a leading global airline company based in Singapore. The company operates a wide range of domestic and international flights, offering both passenger and cargo services.

2QFY25 Financial Preview

  • Expected Profit After Tax and Minority Interests (PATAMI):
    • Estimated to be around S$400 million to S$430 million for the second quarter of FY25.
    • The first half of FY25 PATAMI is expected to align with 51% of the broker’s full-year forecast, which is generally in line but falls below the projections of some analysts.

Key Drivers and Challenges

  1. Passenger Yields:

    • Passenger yields are likely to have continued their downward trend due to increased competition in the market.
    • Although there is heightened competition, this negative effect has been partially mitigated by other factors.
  2. Cargo Demand and Yields:

    • Higher demand for cargo services has provided some support for the company’s earnings.
    • Cargo yields have also seen improvement, which has helped offset the decline in passenger revenues.
  3. Oil Prices:

    • The airline has benefited from lower oil prices, which have reduced operating costs.

Investment Recommendation

  • Current Rating: Reduce
  • Target Price: S$5.88 (CY24F P/BV of 1.1x, +1 standard deviation from the 2011 mean)

Analyst Notes

The report reiterates a “Reduce” rating for Singapore Airlines, as the broker expects the airline to continue experiencing a gradual downdrift in earnings. The target price of S$5.88 reflects the challenges posed by ongoing competition in the passenger sector, despite some positive offsetting factors such as stronger cargo performance and reduced fuel costs.

Hyphens Pharma Defies Economic Headwinds: 22% Revenue Surge Despite Q3 Profit Dip

Hyphens Pharma Reports Solid Q3 and 9M Performance Amid Higher Costs Hyphens Pharma Reports Solid Q3 and 9M Performance Amid Higher Costs Hyphens Pharma International Limited (SGX: 201735688C) has released its quarterly business update...

SIA Engineering (SIE SP): FY25 Earnings Miss, Growth Investments & BUY Recommendation

UOB Kay Hian Private Limited Wednesday, 14 May 2025 SIA Engineering (SIE SP): Riding the Wave of Recovery and Investing in Future Growth SIA Engineering Co Ltd (SIE SP), Asia’s leading service provider for...

Sido Muncul: Riding the Wave of Herbal Growth with Strong Q3 Performance and Promising Outlook

Date: October 28, 2024Broker: UOB Kay Hian Company Overview Sido Muncul is the largest producer of herbal medicine (jamu) and energy drinks in Indonesia. Stock Data Share Price: Rp615 Target Price: Rp800 (Previous Target...